623588-14-7Relevant articles and documents
Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors
Hiranaka, Seiya,Tega, Yuma,Higuchi, Kei,Kurosawa, Toshiki,Deguchi, Yoshiharu,Arata, Mayumi,Ito, Akihiro,Yoshida, Minoru,Nagaoka, Yasuo,Sumiyoshi, Takaaki
supporting information, p. 884 - 888 (2018/09/12)
We designed and synthesized a pyrilamine derivative 1 as a selective class I HDAC inhibitor that targets pyrilamine-sensitive proton-coupled organic cation antiporter (PYSOCA) at the blood-brain barrier (BBB). Introduction of pyrilamine moiety to benzamid
SUBSTITUTED NICOTINAMIDE COMPOUNDS
-
Page/Page column 22, (2009/05/29)
The present invention relates to a novel class of substituted nicotinamides. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplasti
The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors
Hamblett, Christopher L.,Methot, Joey L.,Mampreian, Dawn M.,Sloman, David L.,Stanton, Matthew G.,Kral, Astrid M.,Fleming, Judith C.,Cruz, Jonathan C.,Chenard, Melissa,Ozerova, Nicole,Hitz, Anna M.,Wang, Hongmei,Deshmukh, Sujal V.,Nazef, Naim,Harsch, Andreas,Hughes, Bethany,Dahlberg, William K.,Szewczak, Alex A.,Middleton, Richard E.,Mosley, Ralph T.,Secrist, J. Paul,Miller, Thomas A.
, p. 5300 - 5309 (2008/03/14)
This communication highlights the development of a nicotinamide series of histone deacetylase inhibitors within the benzamide structural class. Extensive exploration around the nicotinamide core led to the discovery of a class I selective HDAC inhibitor that possesses excellent intrinsic and cell-based potency, acceptable ancillary pharmacology, favorable pharmacokinetics, sustained pharmacodynamics in vitro, and achieves in vivo efficacy in an HCT116 xenograft model.
